Techne Corp (NASDAQ:TECH) Big Money Sentiment Change at 1.32

June 29, 2018 - By Gwen Gough

Bio-Techne Corporation (NASDAQ:TECH) Corporate Logo

Techne Corp’s Sentiment

In Q1 2018 Techne Corp (NASDAQ:TECH) big money sentiment increased to 1.32, according to SEC.gov filings. That’s up 0.34, from 2017Q4’s 0.98. 136 investment managers opened new or increased stock positions, while 103 sold and decreased positions in Techne Corp so the sentiment is positive. Funds own 35.01 million shares, down from 35.53 million shares in 2017Q4. Funds holding Techne Corp in top 10 changed to 4 from 2 for an increase of 2. 14 Investors Sold All; 89 Reduced Holdings; 83 increased stakes while 53 investment managers bought stakes.

Significant Techne Corp Investors

As of Q1 2018 Sandhill Capital Partners Llc has 3.74% invested in Techne Corp. As of Q1 2018, 1.99 million shares of Techne Corp are owned by Brown Capital Management Llc. Summit Creek Advisors Llc reported 119,419 shares. The New York-based fund Stone Run Capital Llc have invested about 2.96% of the investment manager’s stock portfolio in Techne Corp. The Minnesota-based fund Mairs & Power Inc holds 1.38 million shares or 2.57% of their stock exposure.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide.The firm is valued at $5.55 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics.The P/E ratio is 49.89. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

The stock increased 0.36% or $0.53 during the last trading session, hitting $147.66.Bio-Techne Corporation has volume of 69,650 shares. Since June 29, 2017 TECH has risen 33.83% and is uptrending. TECH outperformed by 21.26% the S&P500.

Bio-Techne Corporation (NASDAQ:TECH) is awaited to reveal earnings on August, 14., as reported by RTT. Analysts expect change of 15.69 % or $0.16 from previous year’s $1.02 EPS compared to current’s $1.18 EPS. TECH’s profit could hit $44.34M with 31.28 P/E in case $1.18 EPS is published. Wall Street now forecasts 4.42 % EPS growth despite Bio-Techne Corporation last quarter’s EPS of $1.13.

Prudential Finance Inc holds 0.02% or 74,954 shs in its capital. Tributary Capital invested 0.17% of its capital in Bio-Techne Corporation (NASDAQ:TECH). Regions Financial Corp stated it has 72 shs or 0% of all its holdings. Tiaa Cref Mngmt Lc has 121,888 shs for 0.01% of their capital. Dekabank Deutsche Girozentrale holds 0.01% or 14,170 shs in its capital. Nuveen Asset Management reported 1,983 shs. Public Employees Retirement Of Ohio has 0.03% invested in Bio-Techne Corporation (NASDAQ:TECH) for 44,117 shs. Dimensional Fund Advsr Lp owns 210,580 shs. Moreover, Greenleaf Trust has 0% invested in Bio-Techne Corporation (NASDAQ:TECH) for 337 shs. Envestnet Asset reported 9,616 shs. Bogle Ltd Partnership De has invested 0.58% in Bio-Techne Corporation (NASDAQ:TECH). Legal And General Group Pcl holds 44,150 shs. Carroll Fincl Assoc owns 75 shs. Summit Creek Advsr Ltd Liability stated it has 119,419 shs. 509,020 are held by Bankshares Of Ny Mellon Corp.

Bio-Techne Corporation had 3 insider sales and 0 insider buys since February 13, 2018. This’s net activity of $2.13 million. $164,932 worth of Bio-Techne Corporation (NASDAQ:TECH) shs were sold by Eansor Norman David. 5,000 shs were sold by Dinarello Charles A, worth $680,303 on Tuesday, February 13.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Total analysts of 6 have positions in Bio-Techne Corporation (NASDAQ:TECH) as follows: 4 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 67%. Since January 18, 2018 according to StockzIntelligence Inc Bio-Techne Corporation has 9 analyst reports. On Thursday, May 3 the firm has “Buy” rating given by Leerink Swann. On Tuesday, February 6 the firm has “Buy” rating given by Robert W. Baird. On Thursday, March 1 Deutsche Bank maintained the shares of TECH in report with “Buy” rating. On Wednesday, February 7 Craig Hallum maintained the shares of TECH in report with “Buy” rating. The stock rating was downgraded by Deutsche Bank to “Hold” on Wednesday, June 27. On Thursday, January 18 the firm has “Buy” rating by Robert W. Baird given. On Wednesday, February 7 the rating was maintained by Stephens with “Hold”. The company rating was maintained by Deutsche Bank on Thursday, May 3.

For more Bio-Techne Corporation (NASDAQ:TECH) news released briefly go to: Seekingalpha.com, Investingnews.com, Streetinsider.com, Investingnews.com or Investingnews.com. The titles are as follows: “BioTechne to buy Exosome Diagnostics” released on June 25, 2018, “JA Solar Supplies Half-Cell Modules for Solar Plant in Africa” on June 29, 2018, “Bio-Techne (TECH) to Acquire Quad Technologies” with a publish date: June 07, 2018, “Cinedigm Expands its Digital-First Channel” and the last “Adesto Announces Agreement to Acquire Echelon” with publication date: June 29, 2018.

Bio-Techne Corporation (NASDAQ:TECH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.